



February 13, 2017

DCH Health System Partners with Omnicell to Automate Sterile Compounding with Robotic IV Insourcing Solution (RIIS)

Comprehensive, turnkey solution supports safer and more cost-effective compounding

MOUNTAIN VIEW, Calif., Feb. 13, 2017 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that DCH Health System in west Alabama has chosen Omnicell® IV solutions to support their sterile compounding operation to enhance patient safety and reduce pharmacy outsourcing costs.



DCH has partnered with Omnicell to implement the full suite of IV compounding technology across its health system - [i.v.STATION™](#) for non-hazardous robotic compounding, [i.v.STATION ONCO™](#) for hazardous robotic compounding, and [i.v.SOFT® Assist](#) for semi-automated compounding. DCH will also implement the newest offering from Omnicell, the [Robotic IV Insourcing Solution™](#) (RIIS). This unique program combines advanced robotic technology, data and expertly trained pharmacy technician staff into a comprehensive, turnkey package that provides a streamlined path for hospitals to insource their sterile compounding.

"We needed a cost effective way to prepare IV medications that supports our patient safety initiatives," said Tim Martin, PharmD, pharmacy director at DCH Regional Medical Center. "Omnicell's full suite of IV automation technology, including novel programs like RIIS, gives us the tools and resources we need to create a safer, more accurate and ultimately more cost-effective IV compounding operation."

IV medications are complicated and expensive, representing 80 percent of drug spend and 56 percent of overall pharmacy costs.¹

"The challenges of IV compounding—primarily ensuring doses are prepared safely and accurately while complying with increasingly complex regulations—have been deemed too much for some health systems, so they've decided to 'outsource' the problem, and they are willing to pay a significant premium to do so," said Douglas Descalzi, vice president and general manager of IV Solutions at Omnicell. "We've taken these challenges head-on, creating a comprehensive, turnkey approach to insource sterile compounding that leverages operational spend and can be cash flow positive immediately."

Through RIIS, DCH will also have access to novel data services, including [REINVENT](#), a first-of-a-kind global clinical registry that utilizes IV preparation data from sites around the world to help users track performance, identify best practices and gather insights to maximize the value of IV automation technology. Omnicell's [Formulary Tool Kit](#) will provide the health system access to cGMP stability studies to extend beyond use dates using a proven, systematic, repeatable process.

"At Omnicell, we are committed to helping our customers drive improved outcomes. That's the bottom line. Our advanced IV robotic technology is a key piece of that equation, but equally as important are the novel tools, applications support and expertise we provide to drive desired outcomes and enhance patient safety, improve therapy, reduce cost, and facilitate compliance in their IV room," Descalzi said.

About DCH Health System

The DCH Health System, based in Tuscaloosa, Ala., operates DCH Regional Medical Center, a 583-bed regional trauma and referral center; and Northport Medical Center, a 250-bed community hospital with inpatient rehabilitation and psychiatric

units. Fayette Medical Center, a rural hospital and nursing home, is operated under a long-term lease.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omniceil's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-G

Footnotes:

¹ Results from the 2013 ASHP National Survey: The Current State of Pharmacy Practice in Hospitals presented at the 2013 ASHP Midyear Clinical Meeting; Aesynt analysis of pre-mixed, frozen premixed, and add-a-vial systems, March 2014.

Editor's Notes:

1. All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, [omnicell.com](http://www.omnicell.com).
2. Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
3. All other brand or product names may be trademarks or registered trademarks of their respective companies.

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/dch-health-system-partners-with-omnicell-to-automate-sterile-compounding-with-robotic-iv-insourcing-solution-riis-300406104.html>

SOURCE Omnicell, Inc.

News Provided by Acquire Media